Chinook Therapeutics Return on Equity

Chinook Therapeutics (KDNY) currently reports a ROE of -68.12%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Chinook Therapeutics's ROE history and peer comparisons.

Chinook Therapeutics's ROE of -68.12% is higher than the Healthcare sector average of -100.59%. That is roughly 32.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Chinook Therapeutics's current -68.12% should be judged against Healthcare norms (sector average: -100.59%) and against KDNY's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -68.12%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Chinook Therapeutics, and consider following KDNY for alerts when major investors trade the stock.

Chinook Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -68.12% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KDNY with unrelated industries.